Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists. Targher G, Mantovani A, Byrne CD, Tilg H, et al. Gut 2025;74:487-497.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Targher G, Mantovani A, Byrne CD, Tilg H, et al. Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists. Gut 2025;74:487-497.
PMID: 39592207